Faeth Therapeutics (FTH) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$2.84
- Estimate
- -$4.76
- Surprise
- +40.3%
- Score today
- 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Faeth Therapeutics (FTH) reported a narrower loss than forecast — diluted EPS of -$2.84 against the -$4.76 estimate (a 40.3% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates FTH Sell at 5.6/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +40.3% surprise compares with a -5256.8% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Pipeline: PIKTOR
- Quality below floor (2.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $39.06
- Price target
- $47.53
- Stop
- $36.17
- Upside to target
- +21.7%
- Reward-to-risk
- 1.5:1
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-09-03 — shown for context, not personalized investment advice.
FTH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.01B
- P/E (fwd)
- -7.9
- 52-week range
- $7.45–$40.89
- Off 52-week high
- 4.5%
- RSI (14)
- 72
- Volume vs avg
- 0.19×
- Score today
- 5.6/10